Factor V (FV) plays a crucial role in both procoagulant and anticoagulant pathways. It was indicated that -426G/A change in the promoter of the FV gene may have an effect on the occurrence of thrombosis. We aimed to investigate the effect of -426G/A gene variation on thrombus formation in the thrombosis patients of age 0 and 18 years and 70 years and older. The study included 179 patients with the diagnosis of thromboembolism and also 221 healthy individuals as controls. The Polymerase chain reaction-restriction fragment length polymorphism method was used to detect -426G/A. It was observed that carrying AA genotype does not have a significant risk of thrombosis between the patients and controls (for 0-18 age group P = .96, odds ratio [OR]: 1.13 [0.38-3.30], for ≥70 age P = .94, OR: 0.69 [0.11-4.28]). The same results were obtained when FV Leiden mutation carriers were excluded (for 0-18 age group P = .95, OR: 1.15 [0.35-3.78], for ≥70 age P = .89, OR: 0.73 [0.11-4.56]). In this study, an effect on thrombosis of -426G/A polymorphism was not determined.
No takes yet. Share an insight, caveat, or question.
Öztürk et al. (2012) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: